文献速递流行病学与生物统计临床试验与 GCP新药、器械与细胞基因治疗研发

2024年卢旺达马尔堡病毒病:公共卫生与临床应对

Marburg Virus Disease in Rwanda, 2024 - Public Health and Clinical Responses.
PubMed 文献 · N Engl J Med · 2025-01-01

2024年9月27日卢旺达报告马尔堡病毒病暴发,共检测6340例疑似患者,66例实验室确诊,其中51例(77%)为医务人员。病死率为23%(66例中15例死亡)。实施遏制措施、先进支持治疗及研究性药物和疫苗紧急使用可能有助于降低死亡率。

要点

  • 66例确诊马尔堡病毒病中77%(51例)为医务人员,病死率23%(15/66)。
  • 中位估计潜伏期10天(IQR 8–13),症状出现在入院前中位2天(IQR 1–3)。
  • 1710名一线工作人员和高风险接触者在2期临床试验紧急使用授权下接种ChAd3-MARV疫苗。

核心结论

  • 实施遏制措施、先进支持治疗及获取研究性对策可能有助于降低本次暴发的马尔堡病毒病死亡率。
  • 加强监测、改善医疗机构感染预防与控制、确保及时部署医疗对策对减轻未来丝状病毒病暴发影响至关重要。

研究设计与样本

  • 对暴发应对各支柱汇总数据进行回顾性流行病学和临床分析,并对接受支持治疗和研究性治疗药物的患者进行病例系列分析。
  • 共检测6340例疑似马尔堡病毒病患者,其中66例实验室确诊。

主要发现

  • 66例实验室确诊马尔堡病毒病中51例(77%)为医务人员。
  • 中位估计潜伏期为10天(四分位距8至13),症状出现在入院前中位2天(四分位距1至3)。
  • 流行病学调查结果高度提示暴发为人畜共患起源:发现一名指示患者曾在采矿点接触埃及果蝠。
  • 暴发病死率为23%(66例患者中15例死亡)。
  • 瑞德西韦和单克隆抗体MBP091在扩大可及和临床试验方案下使用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: On September 27, 2024, Rwanda reported an outbreak of Marburg virus disease (MVD), after a cluster of cases of viral hemorrhagic fever was detected at two urban hospitals. METHODS: We report key aspects of the epidemiology, clinical manifestations, and treatment of MVD during this outbreak, as well as the overall response to the outbreak. We performed a retrospective epidemiologic and clinical analysis of data compiled across all pillars of the outbreak response and a case-series analysis to characterize clinical features, disease progression, and outcomes among patients who received supportive care and investigational therapeutic agents. RESULTS: Among the 6340 patients with suspected MVD who underwent testing, 66 had laboratory-confirmed MVD, 51 (77%) of whom were health care workers. The median estimated incubation period was 10 days (interquartile range, 8 to 13), and symptom onset occurred a median of 2 days (interquartile range, 1 to 3) before hospital admission. The results of epidemiologic investigations were highly suggestive of a zoonotic origin of the outbreak: an index patient was identified who had been exposed to Egyptian fruit bats at a mining site. The case fatality rate in the outbreak was 23% (15 deaths among 66 patients). Remdesivir and the monoclonal antibody MBP091 were used under expanded access and clinical trial protocols. In addition, 1710 frontline workers and high-risk contacts received the chimpanzee adenovirus 3-vectored vaccine ChAd3-MARV under emergency use authorization in a phase 2 clinical trial. CONCLUSIONS: Implementation of containment measures, advanced supportive care, and access to investigational countermeasures may have contributed to reduced mortality from MVD in this outbreak. Enhancing surveillance, improving infection prevention and control in health care settings, and ensuring timely deployment of medical countermeasures will be critical for mitigating the effects of future filovirus disease outbreaks.

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Nsanzimana S, Remera E, Nkeshimana M, et al. Marburg Virus Disease in Rwanda, 2024 - Public Health and Clinical Responses. N Engl J Med. 2025. PMID: 40929633. doi:10.1056/NEJMoa2415816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。